about
Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic interventionLipid mediators are critical in resolving inflammation: a review of the emerging roles of eicosanoids in diabetes mellitusConstrictor prostanoids and uridine adenosine tetraphosphate: vascular mediators and therapeutic targets in hypertension and diabetesCYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid ω-hydroxylase activitiesPannexin channel and connexin hemichannel expression in vascular function and inflammationEndothelium-derived vasoactive factors and hypertension: possible roles in pathogenesis and as treatment targets.Design of Fluorine-Containing 3,4-Diarylfuran-2(5H)-ones as Selective COX-1 Inhibitors.Eryptosis as a marker of Parkinson's diseaseEicosanoid Production following One Bout of Exercise in Middle-Aged African American Pre- and Stage 1 Hypertensives.Eicosanoids, β-cell function, and diabetesRegulation of the human coronary microcirculation.Effects of insulin resistance and testosterone on the participation of cyclooxygenase isoforms in vascular reactivity.AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/β-catenin signaling pathwayCyclic stretch induces cyclooxygenase-2 gene expression in vascular endothelial cells via activation of nuclear factor kappa-betaCirculating blood endothelial nitric oxide synthase contributes to the regulation of systemic blood pressure and nitrite homeostasis.The ubiquitin-proteasome pathway and endothelial (dys)function.COX-mediated endothelium-dependent contractions: from the past to recent discoveries.Nitric oxide: orchestrator of endothelium-dependent responses.Cardiovascular Adaptations to Exercise Training.Urinary 11-dehydro-thromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease.Gene expression and gene associations during the development of heart failure with preserved ejection fraction in the Dahl salt sensitive model of hypertension.Psoralea corylifolia extract induces vasodilation in rat arteries through both endothelium-dependent and -independent mechanisms involving inhibition of TRPC3 channel activity and elaboration of prostaglandin.Effects of Toll-Like Receptor 4 Antagonists Against Cerebral Vasospasm After Experimental Subarachnoid Hemorrhage in Mice.Connexins and Pannexins in Vascular Function and Disease
P2860
Q26997377-A1B0A50D-E993-4902-902A-5267F1E5BFDEQ28080521-341ECEEB-862E-4660-9751-96B98C47CDBEQ28081462-CBF75644-15DB-4577-A225-E513F7FCF6C1Q28290987-68485878-4A00-45CA-A3EC-361799CCF712Q30274918-AD745490-BF12-4170-B2DD-1DD94F17A4B9Q34023606-28BE6F97-405E-4C8E-9967-3074319D2D52Q34519695-552CF17B-83A9-4B16-98FD-8CD81F96D55CQ34585744-8D07DDDD-D4DF-4558-B022-4D2D59C2F6DCQ35001163-914F6D3B-3152-47CA-8F8B-B86350743E2DQ35129888-49F09F06-BA6E-428F-BCDA-D1DE08A7820BQ35836547-5C656540-E405-4D2F-A547-0A55376CDDA7Q36890451-8F39E941-3A17-4759-8516-F690E3EF7E25Q36928338-A2E4CC79-BD0F-4813-9993-EBB3A58EC882Q37390752-6F8E415E-4833-42F8-BF3D-B418ACA907C8Q37394378-BD8166C2-3A1C-48A3-8754-17EE663ADC54Q37600516-2B94B610-FD18-422C-A5CF-B5A9E4B3B1DCQ37780105-A4E1A768-6572-4059-8CA2-BA2FB0C64325Q37927098-8A02354E-A5D6-48E0-BEFC-14E647420E05Q38693262-8D43F779-F919-4E16-9D8F-067B414093DEQ47385143-189A3729-C6C6-4DCE-BA82-4D2B25C6A089Q47400069-2BC0992B-FA16-44E2-B374-B00A5D31DDF7Q47856568-20EE8265-61DE-449E-8A14-423637F111BBQ48302008-A2407DAF-5B5C-4DB4-A349-F3A641A13861Q56363256-ABB7FA31-9739-4855-8C49-53E790EA9265
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
COX-1 and vascular disease.
@en
COX-1 and vascular disease.
@nl
type
label
COX-1 and vascular disease.
@en
COX-1 and vascular disease.
@nl
prefLabel
COX-1 and vascular disease.
@en
COX-1 and vascular disease.
@nl
P2860
P356
P1476
COX-1 and vascular disease.
@en
P2093
P M Vanhoutte
P2860
P304
P356
10.1038/CLPT.2009.108
P407
P577
2009-06-24T00:00:00Z